Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Odds Ratio01:09

Odds Ratio

98
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
98
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

114
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
114
Hazard Ratio01:12

Hazard Ratio

78
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
78
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

3.3K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
3.3K
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

26
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
26
Randomized Experiments01:13

Randomized Experiments

6.7K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
6.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Minimum noninferiority dose for phase I clinical trials with immunotherapy.

Biometrics·2026
Same author

Patient Retreat in Dose Escalation for Phase I Clinical Trials With Rare Diseases.

Statistics in medicine·2026
Same author

Decision Tables for Calibration-Free Odds Design in Phase I Clinical Trials.

JCO precision oncology·2025
Same author

Bayesian generalized method of moments applied to pseudo-observations in survival analysis.

Lifetime data analysis·2025
Same author

Unit information Dirichlet process prior.

Biometrics·2024
Same author

Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials.

Statistics in medicine·2024
Same journal

Equity and Automation in Clinical Trial Screening: Risks and Responsibilities of Artificial Intelligence‑Enabled Matching and Enrollment Systems.

JCO clinical cancer informatics·2026
Same journal

Patient-Reported Symptom Burden Among Thyroid Cancer Survivors: Retrospective Cohort Study.

JCO clinical cancer informatics·2026
Same journal

Rule-Based Algorithm to Identify Recurrent Non-Hodgkin Lymphoma in Electronic Health Data.

JCO clinical cancer informatics·2026
Same journal

Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101.

JCO clinical cancer informatics·2026
Same journal

Effect of a Multidimensional Digital Health Intervention on Quality of Life in Breast Cancer Survivors: A Randomized Controlled Trial.

JCO clinical cancer informatics·2026
Same journal

Can Small Open-Source Language Models With Retrieval-Augmented Generation Match GPT-4 Performance in Breast Cancer Clinical Decision Support?

JCO clinical cancer informatics·2026
查看所有相关文章

相关实验视频

Updated: May 30, 2025

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.7K

首席财务官:在临床试验中检测剂量的贝叶斯设计.

Jialu Fang1, Ninghao Zhang1, Wenliang Wang1

  • 1School of Computing and Data Science, The University of Hong Kong, Hong Kong, China.

JCO clinical cancer informatics
|January 31, 2025
PubMed
概括
此摘要是机器生成的。

我们开发了用户友好的R和Shiny软件,用于在临床试验中实施先进的无校准赔率 (CFO) 类型设计. 这些工具通过整合随机化和各种CFO设计变体来提高剂量检测的准确性和效率.

更多相关视频

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

相关实验视频

Last Updated: May 30, 2025

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.7K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

科学领域:

  • 生物统计学 生物统计学
  • 临床试验设计 临床试验设计
  • 药物指标 (Pharmacometrics) 是一个指标.

背景情况:

  • 无校准概率 (CFO) 类型的设计是临床试验中可靠且无模型的剂量发现的当前标准.
  • 对CFO类型设计的广泛采用的一个重要障碍是缺乏可访问的实施工具.

研究的目的:

  • 开发用户友好的 R 包和 Shiny 基于网络的软件,用于实际实现 CFO 类型设计.
  • 将随机化纳入CFO框架,创建随机化的CFO (rCFO) 设计.

主要方法:

  • 开发了R包"CFO"和一个名为"CFO套件"的交互式R Shiny网络应用程序.
  • 通过随机化整合了一个勘探开发机制,以引入rCFO设计.
  • 嵌入了各种CFO设计变体,包括2dCFO,aCFO,TITE-CFO,fCFO,TITE-aCFO和分数-aCFO.

主要成果:

  • 首席财务官包和首席财务官套件为各种临床试验设置提供了一个全面的工具套件.
  • 提供了用于剂量确定,最大耐受剂量选择和通过模拟进行性能评估的功能.
  • 输出包括模拟和试验结果的文字和图形表示.

结论:

  • 首席财务官包和首席财务官套件为在I期临床试验中实施首席财务官类型设计提供了灵活和全面的工具.
  • 这项工作整合了现有的CFO类型设计,使得新的试验设计能够提高性能.
  • 该用户友好的软件促进了先进的统计方法的采用,并加强了生物统计学家和临床医生的合作,以提高试验的效率和准确性.